American Journal of Cardiology
Volume 104, Issue 12 , Pages 1647-1653, 15 December 2009

Optimal Medical Therapy With or Without Percutaneous Coronary Intervention for Patients With Stable Coronary Artery Disease and Chronic Kidney Disease

  • Steven P. Sedlis, MD

      Affiliations

    • Veterans Affairs New York Harbor Health Care System, and New York University School of Medicine, New York, New York
    • Corresponding Author InformationCorresponding author: Tel: (212) 951-3335; fax: (212) 951-3334
  • ,
  • Claudine T. Jurkovitz, MD, MPH

      Affiliations

    • Christiana Care Health System, Newark, Delaware
  • ,
  • Pamela M. Hartigan, PhD

      Affiliations

    • Veterans Affairs Cooperative Studies Program Coordinating Center and Veterans Affairs Connecticut Health Care System, West Haven, Connecticut
  • ,
  • David S. Goldfarb, MD

      Affiliations

    • Veterans Affairs New York Harbor Health Care System, and New York University School of Medicine, New York, New York
  • ,
  • Jeffrey D. Lorin, MD

      Affiliations

    • Veterans Affairs New York Harbor Health Care System, and New York University School of Medicine, New York, New York
  • ,
  • Marcin Dada, MD

      Affiliations

    • Hartford Hospital, Hartford, Connecticut
  • ,
  • David J. Maron, MD

      Affiliations

    • Vanderbilt University Medical Center, Nashville, Tennessee
  • ,
  • John A. Spertus, MD

      Affiliations

    • Mid America Heart Institute, Kansas City, Missiouri
  • ,
  • G.B. John Mancini, MD

      Affiliations

    • Vancouver Hospital, Cardiovascular Imaging Research Core Laboratory, University of British Columbia, Vancouver, British Columbia, Canada
  • ,
  • Koon K. Teo, MBBCh, PhD

      Affiliations

    • McMaster University Medical Centre, Hamilton, Ontario, Canada
  • ,
  • Robert A. O'Rourke, MD

      Affiliations

    • Veterans Affairs South Texas Health Care System, San Antonio, Texas
  • ,
  • William E. Boden, MD

      Affiliations

    • Veterans Affairs Western New York Health Care System and Kaleida Health, Buffalo, New York
  • ,
  • William S. Weintraub, MD

      Affiliations

    • Christiana Care Health System, Newark, Delaware
  • ,
  • COURAGE Study Investigators

Received 12 June 2009; received in revised form 19 July 2009; accepted 19 July 2009.

Chronic kidney disease (CKD) is a risk factor for poor outcomes in patients with coronary artery disease (CAD), but it is unknown whether CKD influences the efficacy of alternative CAD treatment strategies. Thus, we compared outcomes in stable CAD patients with and without CKD randomized to percutaneous coronary intervention (PCI) and optimal medical therapy (OMT) or OMT alone in a post hoc analysis of the 2,287 patient COURAGE study. At baseline, 320 patients (14%) had CKD defined as a glomerular filtration rate of <60 mL/min/1.73 m2, as estimated by the abbreviated 4-variable Modification of Diet in Renal Disease equation. The patients with CKD were older (68 ± 9 vs 61 ± 10 years; p <0.001) and more often had diabetes mellitus (42% vs 33%; p = 0.002), hypertension (81% vs 65%; p <0.03), heart failure (13% vs 3.4%; p <001), and three-vessel CAD (37% vs 29%, p = 0.01). After adjustment for these differences, CKD remained an independent predictor of death or nonfatal myocardial infarction (hazard ratio 1.48, 95% confidence interval 1.15 to 1.90). PCI had no effect on these outcomes. Furthermore, at 36 months, a similar percentage of patients with CKD treated with OMT (70%) and PCI plus OMT (76%) were angina free compared to patients without CKD. In conclusion, CKD is an important determinant of clinical outcomes in patients with stable CAD, regardless of the treatment strategy. Although PCI did not reduce the risk of death or myocardial infarction when added to OMT for patients with CKD, it also was not associated with worse outcomes in this high-risk group.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 The trial was sponsored and oversight was provided by the Cooperative Studies Program of the US Department of Veterans Affairs Office of Research and Development. Additional funding was provided by the Canadian Institutes of Health Research. Supplemental corporate support consisted of unrestricted research grants payable to the Department of Veterans Affairs.

PII: S0002-9149(09)01474-X

doi:10.1016/j.amjcard.2009.07.043

American Journal of Cardiology
Volume 104, Issue 12 , Pages 1647-1653, 15 December 2009